NURIX THERAPEUTICS, INC. (NRIX) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-05-31..
Dividend safety
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -341.35M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-05-31 | (m) | $-341.35M | (m) |
| 2026-02-28 | (m) | $-295.28M | (m) |
| 2025-11-30 | (m) | $-264.46M | (m) |
| 2025-08-31 | (m) | $-244.78M | (m) |
| 2025-05-31 | (m) | $-207.32M | (m) |
| 2025-02-28 | (m) | $-208.40M | (m) |
| 2024-11-30 | (m) | $-193.57M | (m) |
| 2024-08-31 | (m) | $-176.98M | (m) |
| 2024-05-31 | (m) | $-165.00M | (m) |
| 2024-02-29 | (m) | $-144.73M | (m) |
| 2023-11-30 | (m) | $-143.95M | (m) |
| 2023-08-31 | (m) | $-148.71M | (m) |
| 2023-05-31 | (m) | $-157.44M | (m) |
| 2023-02-28 | (m) | $-178.56M | (m) |
| 2022-11-30 | (m) | $-180.36M | (m) |
| 2022-08-31 | (m) | $-171.34M | (m) |
| 2022-05-31 | (m) | $-154.47M | (m) |
| 2022-02-28 | (m) | $-135.45M | (m) |
| 2021-11-30 | (m) | $-117.19M | (m) |
| 2021-08-31 | (m) | $-99.41M | (m) |
| 2021-05-31 | (m) | $-89.09M | (m) |
| 2021-02-28 | (m) | $-55.13M | (m) |
| 2020-11-30 | (m) | $-43.24M | (m) |
| 2020-08-31 | (m) | (m) | (m) |
| 2020-05-31 | (m) | (m) | (m) |
| 2020-02-29 | (m) | (m) | (m) |
| 2019-11-30 | (m) | $-21.70M | (m) |
| 2019-08-31 | (m) | (m) | (m) |
| 2019-05-31 | (m) | (m) | (m) |
| 2019-02-28 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |